The prescription-only COVID-19 treatment Lagevrio (molnupiravir) is generally administered as whole capsules as outlined in the TGA PI. While the recommendation is to swallow the capsules, if this is not possible, and if alternative treatments are not available or not suitable, the manufacturer has advised the procedure set out in the NPS Medicinewise guidelines allows preparation of an oral solution (Instructions for the preparation of molnupiravir oral solution). Please note this advice is based on preliminary data and should be limited to those circumstances where there is no other option. This is regarded as an ‘off label’ use – it is recommended this decision be documented in the patient record and consent should be obtained from the patient or their designated decision-maker for use of the treatment in this way.
To find more information about:
COVID-19 oral antiviral medicines in residential aged care | nps.org.au
Alternative treatment options, consensus recommendations and flowchart
Oral treatments for COVID-19 | Australian Government Department of Health